Age-related Vision Dysfunction - Market Insights, Epidemiology, and Market Forecast—2030

DelveInsight’s ‘Age-related Vision Dysfunction - Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the Age-related Vision Dysfunction, historical and forecasted epidemiology as well as the Age-related Vision Dysfunction market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Age-related Vision Dysfunction market report provides current treatment practices, emerging drugs, Age-related Vision Dysfunction market share of the individual therapies, current and forecasted Age-related Vision Dysfunction market size from 2018 to 2030 segmented by seven major markets. The Report also covers current Age-related Vision Dysfunction treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2018–2030
Age-related Vision Dysfunction: Disease Understanding and Treatment Algorithm
Age-related Vision Dysfunction Overview

The International Classification of Diseases 11 (2018) classifies vision impairment into two groups, distance and near presenting vision impairment. Beginning in the early to mid-forties, most adults may start to experience problems with their ability to see clearly at close distances, especially for reading and computer tasks. This normal change in the eye’s focusing ability will continue to progress over time. Vision loss among the elderly population is a major health care problem. Approximately one in three people have some form of vision-reducing eye disease by the age of 65. Beginning in the early to mid-forties, most adults may start to experience problems with their ability to see clearly at close distances, especially for reading and computer tasks. This normal change in the eye’s focusing ability will continue to progress over time. Adults over 40 may be particularly at risk for the development of eye and vision problems.

The process of aging contributes to visual loss through the deterioration of the function of the eye tissues and increased ocular pathology in the elderly. The process of pathology takes place over months to years, and patients usually have minimal symptoms initially. The five major causes of visual impairment in the elderly are presbyopia, age-related cataracts, age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy.

Aging changes in various parts of the eye can result in several noticeable differences in how well a person can see. While not everyone will experience the same level of symptoms, the following are common age-related vision changes, some of the common symptoms include difficulty reading and doing close work, problems with glare, changes in color perception, reduced tear production, seeing distorted images, loss of side vision, seeing floaters and flashes, and fluctuating vision.


1. Key Insights
2. Report Introduction
3. Age-related Vision Dysfunction Market Overview at a Glance
3.1. Market Share (%) Distribution of Age-related Vision Dysfunction in 2018
3.2. Market Share (%) Distribution of Age-related Vision Dysfunction in 2030
4. Executive Summary of Age-related Vision Dysfunction
5. Epidemiology and Market Methodology
6. Disease Background and Overview
6.1. Introduction
6.2. Causes of Age-related Vision Dysfunction
6.2.1. Age-related Macular Degeneration (AMD)
6.2.2. Diabetic Retinopathy (DR)
6.2.3. Cataract
6.2.4. Glaucoma
6.2.5. Presbyopia
6.3. Signs and symptoms of Age-related Vision Dysfunction
6.4. Risk factors of Age-related Vision Dysfunction
6.5. Pathophysiology of Age-related Vision Dysfunction
7. Diagnosis of Age-related Vision Dysfunction
7.1. Patient History
7.2. Preliminary tests
7.3. Vision Acuity
7.4. Refraction
7.5. Fundus Fluorescein Angiography (FFA)
7.6. Indocyanine green angiography (ICG)
7.7. Amsler Grid Test
7.8. Visual Field Test
7.9. Tonometry Test
7.10. Ophthalmoscopy
7.11. Slit-lamp Examination
8. Prevention of Age-related Vision Dysfunction
9. Diagnostic Guidelines
9.1. American Family Physician guidelines
9.2. The National Institute for Clinical Excellence (NICE) – Diagnostic Guidelines for AMD
10. Current Treatment Practices: Age-related Vision Dysfunction
10.1. Treatments for advanced Diabetic Retinopathy
10.2. Treatments for Cataract
10.3. Treatments for AMD
10.4. Treatments for Glaucoma
10.5. Treatments for Presbyopia
11. Treatment Guidelines
11.1. American Family Physician Guidelines
11.2. World Health Organization (WHO) Guidelines
11.3. Management Strategies for Correction of Presbyopia – The American Optometric Association
11.3.1. General Considerations
11.3.2. Patient Education
11.3.3. Prognosis and Follow-up
11.4. NICE guidance for corneal inlay implantation for correction of presbyopia
11.5. Management guidelines by the American Academy of Ophthalmology
11.6. American Academy of Ophthalmology Guidelines for AMD
11.7. Guidelines of the Royal College of Ophthalmologists – Treatment of Neovascular AMD
11.8. The National Institute for Clinical Excellence (NICE) – Treatment Guidelines for AMD
11.8.1. Pharmacological management of AMD
11.8.2. Non-pharmacological management of AMD
11.9. American Academy of Ophthalmology – Guidelines for Diabetic Retinopathy
11.10. International Council of Ophthalmology (ICO) – Guidelines for Diabetic Retinopathy
11.11. International Council of Ophthalmology (ICO) – Guidelines for Cataract
11.12. International Council of Ophthalmology – Guidelines for AMD
11.13. American Academy of Ophthalmology – Guidelines for Cataract
11.14. American Academy of Ophthalmology – Guidelines for Glaucoma
12. Epidemiology and Patient Population
12.1. Key Findings
12.2. Epidemiology of Age-related vision dysfunction
12.3. Epidemiology Scenario: 7MM
12.3.1. Total Prevalent Cases of Age-related vision dysfunction
12.3.2. Total Diagnosed Cases of Age-related vision dysfunction
12.3.3. Severity-specific Cases of Age-related vision dysfunction
12.3.4. Total Treated Cases of Age-related vision dysfunction
13. The United States
13.1. Total Prevalent Cases of Age-related vision dysfunction
13.2. Total Diagnosed Cases of Age-related vision dysfunction
13.3. Severity-specific Cases of Age-related vision dysfunction
13.4. Total Treated Cases of Age-related vision dysfunction
14. EU-5
14.1. Germany
14.1.1. Total Prevalent Cases of Age-related vision dysfunction
14.1.2. Total Diagnosed Cases of Age-related vision dysfunction
14.1.3. Severity-specific Cases of Age-related vision dysfunction
14.1.4. Total Treated Cases of Age-related vision dysfunction
14.2. France
14.2.1. Total Prevalent Cases of Age-related vision dysfunction
14.2.2. Total Diagnosed Cases of Age-related vision dysfunction
14.2.3. Severity-specific Cases of Age-related vision dysfunction
14.2.4. Total Treated Cases of Age-related vision dysfunction
14.3. Italy
14.3.1. Total Prevalent Cases of Age-related vision dysfunction
14.3.2. Total Diagnosed Cases of Age-related vision dysfunction
14.3.3. Severity-specific Cases of Age-related vision dysfunction
14.3.4. Total Treated Cases of Age-related vision dysfunction
14.4. Spain
14.4.1. Total Prevalent Cases of Age-related vision dysfunction
14.4.2. Total Diagnosed Cases of Age-related vision dysfunction
14.4.3. Severity-specific Cases of Age-related vision dysfunction
14.4.4. Total Treated Cases of Age-related vision dysfunction
14.5. The United Kingdom
14.5.1. Total Prevalent Cases of Age-related vision dysfunction
14.5.2. Total Diagnosed Cases of Age-related vision dysfunction
14.5.3. Severity-specific Cases of Age-related vision dysfunction
14.5.4. Total Treated Cases of Age-related vision dysfunction
15. Japan
15.1. Total Prevalent Cases of Age-related vision dysfunction
15.2. Total Diagnosed Cases of Age-related vision dysfunction
15.3. Severity-specific Cases of Age-related vision dysfunction
15.4. Total Treated Cases of Age-related vision dysfunction
16. Patient Journey
17. Key Endpoints in Age-related Vision Dysfunction Clinical Trials
18. Marketed Therapies
18.1. Rocklatan (Latanoprast; Netarsudil Dimesylate): Aerie Pharmaceuticals
18.1.1. Drug Description
18.1.2. Regulatory Milestones
18.1.3. Other Developmental Activities
18.1.4. Pivotal Clinical Trial
18.2. Eybelis Ophthalmic Solution (DE-117, Omidenepag isopropyl): Santen Pharmaceutical/Ube Industries
18.2.1. Drug Description
18.2.2. Regulatory Milestones
18.2.3. Other Developmental Activities
18.2.4. Pivotal Clinical Trial
18.2.5. Ongoing Current Pipeline Activity
18.3. Xelpros (Latanoprost Ophthalmic Emulsion): Sun Pharma Advanced Research Company Limited
18.3.1. Drug Description
18.3.2. Regulatory Milestones
18.3.3. Other Developmental Activities
18.3.4. Pivotal Clinical Trial
18.4. Rhopressa (Netarsudil mesylate): Aerie Pharmaceuticals
18.4.1. Product Description
18.4.2. Regulatory Milestones
18.4.3. Other Developmental Activities
18.4.4. Pivotal Clinical Trial
18.4.5. Ongoing Current Pipeline Activity
18.5. Vyzulta (Latanoprostene Bunod Ophthalmic Solution): Bausch & Lomb/Nicox
18.5.1. Product Description
18.5.2. Regulatory Milestones
18.5.3. Other Developmental Activities
18.5.4. Pivotal Clinical Trial
18.6. Glanatec (Ripasudil hydrochloride hydrate): D Western Therapeutics Institute/Kowa Pharmaceutical
18.6.1. Product Description
18.6.2. Regulatory Milestones
18.6.3. Other Developmental Activities
18.6.4. Pivotal Clinical Trial
18.7. Simbrinza (Brinzolamide/Brimonidine Tartrate Ophthalmic Suspension): Novartis
18.7.1. Drug Description
18.7.2. Regulatory Milestones
18.7.3. Other Developmental Activities
18.7.4. Pivotal Clinical Trial
18.8. Tapcom/DE-111 (Tafluprost/Timolol Maleate; Taptiqom): Santen Pharmaceutical
18.8.1. Product Description
18.8.2. Regulatory Milestones
18.8.3. Other Developmental Activities
18.8.4. Pivotal Clinical Trial
18.8.5. Safety and Efficacy
18.9. Azarga/Azorga (Brinzolamide/Timolol): Novartis
18.9.1. Drug Description
18.9.2. Regulatory Milestones
18.9.3. Pivotal Clinical Trial
18.10. Combigan (Brimonidine/timolol): Allergan (AbbVie)
18.10.1. Product Description
18.10.2. Regulatory Milestones
18.10.3. Other Developmental Activities
18.10.4. Pivotal Clinical Trial
18.11. Lucentis (Ranibizumab): Genentech/Novartis
18.11.1. Drug Description
18.11.2. Regulatory Milestones
18.11.3. Other Developmental Activities
18.11.4. Pivotal Clinical Trial
18.11.5. Ongoing Current Pipeline Activity
18.12. Eylea (Aflibercept): Bayer/Regeneron Pharmaceuticals/Santen
18.12.1. Drug Description
18.12.2. Regulatory Milestones
18.12.3. Other Developmental Activities
18.12.4. Pivotal Clinical Trial
18.12.5. Ongoing Current Pipeline Activity
18.13. Beovu (Brolucizumab): Novartis
18.13.1. Drug Description
18.13.2. Regulatory Milestones
18.13.3. Other Developmental Activities
18.13.4. Pivotal Clinical Trial
18.13.5. Ongoing Current Pipeline Activity
19. Emerging Therapies
19.1. AGN-190584: Allergan (acquired by AbbVie)
19.1.1. Product Description
19.1.2. Other Developmental Activities
19.1.3. Clinical Development
19.1.4. Safety and Efficacy
19.2. MicroLine (Pilocarpine Ophthalmic): Eyenovia
19.2.1. Product Description
19.2.2. Other Developmental Activities
19.2.3. Clinical Development
19.3. PresbiDrops (CSF-1): Orasis Pharmaceuticals
19.3.1. Product Description
19.3.2. Other Developmental Activities
19.3.3. Clinical Development
19.3.4. Safety and Efficacy
19.4. Zimura (Avacincaptad pegol): IVERIC Bio
19.4.1. Product Description
19.4.2. Other Developmental Activities
19.4.3. Clinical Development
19.4.4. Safety and Efficacy
19.5. ALK-001: Alkeus Pharmaceuticals
19.5.1. Product Description
19.5.2. Other Developmental Activities
19.5.3. Clinical Development
19.6. ONS-5010/Lytenava (Bevacizumab-vikg): Outlook Therapeutics
19.6.1. Product Description
19.6.2. Other Developmental Activities
19.6.3. Clinical Development
19.7. KSI-301: Kodiak Sciences
19.7.1. Product Description
19.7.2. Other Developmental Activities
19.7.3. Clinical Development
19.7.4. Safety and Eficacy
19.8. Faricimab: Roche
19.8.1. Product Description
19.8.2. Clinical Development
19.8.3. Safety and Eficacy
19.9. Abicipar: Allergan (AbbVie)/Molecular Partners
19.9.1. Product Description
19.9.2. Other Developmental Activities
19.9.3. Clinical Development
19.9.4. Safety and Efficacy
19.10. RGX-314- Regenxbio
19.10.1. Product Description
19.10.2. Other Developmental Activities
19.10.3. Clinical Development
19.10.4. Safety and Efficacy
19.11. Beovu (RTH258; Brolucizumab): Novartis
19.11.1. Product Description
19.11.2. Other Developmental Activities
19.11.3. Clinical Development
19.11.4. Safety and Efficacy
19.12. STN1013001/DE-130A (Catioprost; latanoprost emulsion): Santen SAS
19.12.1. Product Description
19.12.2. Other Developmental Activities
19.12.3. Clinical Development
19.13. NCX 470: Nicox Ophthalmics
19.13.1. Product Description
19.13.2. Other Developmental Activities
19.13.3. Clinical Development
19.13.4. Safety and Efficacy
19.14. OTX-TP (travoprost ophthalmic insert): Ocular Therapeutix
19.14.1. Product Description
19.14.2. Other Developmental Activities
19.14.3. Clinical Development
19.14.4. Safety and Eficacy
19.15. PDP-716: Sun Pharma Advanced Research Company Limited
19.15.1. Product Description
19.15.2. Other Developmental Activities
19.15.3. Clinical Development
19.16. OPT-302: Opthea
19.16.1. Product Description
19.16.2. Other Developmental Activities
19.16.3. Clinical Development
19.16.4. Safety and Efficacy
19.17. Lumitin (Conbercept): Chengdu Kanghong Pharmaceuticals
19.17.1. Product Description
19.17.2. Other Developmental Activities
19.17.3. Clinical Development
19.18. AKST4290 (Lazucirnon): Alkahest
19.18.1. Product Description
19.18.2. Other Developmental Activities
19.18.3. Clinical Development
19.19. GT005: Gyroscope Therapeutics
19.19.1. Product Description
19.19.2. Other Developmental Activities
19.19.3. Clinical Development
19.19.4. Safety and Efficacy
19.20. ADVM-022: Adverum Biotechnologies
19.20.1. Product Description
19.20.2. Other Developmental Activities
19.20.3. Clinical Development
19.20.4. Safety and Efficacy
19.21. Emixustat hydrochloride (emixustat): Kubota Vision
19.21.1. Product Description
19.21.2. Other Developmental Activities
19.21.3. Clinical Development
19.21.4. Safety and Efficacy
19.22. KVD001: KalVista Pharmaceuticals
19.22.1. Product Description
19.22.2. Other Developmental Activities
19.22.3. Clinical Development
19.22.4. Safety and Efficacy
19.23. Luminate (ALG-1001, Risuteganib): Allergo Opthalmics/Baush Health
19.23.1. Product Description
19.23.2. Other Developmental Activities
19.23.3. Clinical Development
19.23.4. Safety and Efficacy
19.24. GB-102: Graybug Vision
19.24.1. Product Descritpion
19.24.2. Other Developmental Activities
19.24.3. Clinical Development
19.24.4. Safety and Efficacy
19.25. Razuprotafib (AKB-9778): Aerpio Pharmaceuticals
19.25.1. Product Description
19.25.2. Other Developmental Activities
19.25.3. Clinical Development
19.25.4. Safety and Efficacy
19.26. Nyxol (Phentolamine Mesylate): Ocuphire Pharma
19.26.1. Product Description
19.26.2. Other Developmental Activities
19.26.3. Clinical Development
19.27. STN1012600 (DE-126): Santen Pharmaceutical
19.27.1. Product Description
19.27.2. Other Developmental Activities
19.27.3. Clinical Development
19.27.4. Safety and Efficacy
20. Age-related Vision Dysfunction: 7 Major Market Analysis
20.1. Key Findings
20.2. Market Outlook
20.3. 7MM Market Size
20.3.1. Total Market Size of Age-related Vision Dysfunction in the 7MM
20.3.2. Market Size of Age-related Vision Dysfunction by Therapies in the 7MM
21. The United States Market Size
21.1. Total Market Size of Age-related Vision Dysfunction in the United States
21.2. Market Size of Age-related Vision Dysfunction by Therapies in the United States
22. EU-5 Market Size
22.1. Germany
22.1.1. Total Market size of Age-related Vision Dysfunction in Germany
22.1.2. Market Size of Age-related Vision Dysfunction by Therapies in Germany
22.2. France
22.2.1. Total Market size of Age-related Vision Dysfunction in France
22.2.2. Market Size of Age-related Vision Dysfunction by Therapies in France
22.3. Italy
22.3.1. Total Market size of Age-related Vision Dysfunction in Italy
22.3.2. Market Size of Age-related Vision Dysfunction by Therapies in Italy
22.4. Spain
22.4.1. Total Market size of Age-related Vision Dysfunction in Spain
22.4.2. Market Size of Age-related Vision Dysfunction by Therapies in Spain
22.5. The United Kingdom
22.5.1. Total Market size of Age-related Vision Dysfunction in the United Kingdom
22.5.2. Market Size of Age-related Vision Dysfunction by Therapies in the United Kingdom
23. Japan
23.1. Total Market size of Age-related Vision Dysfunction in Japan
23.2. Market Size of Age-related Vision Dysfunction by Therapies in Japan
24. Market Access and Reimbursement
24.1. Key HTA decisions for Age-related Vision Dysfunction
24.1.1. AMD
24.1.2. Glaucoma
24.1.3. Diabetic Retinopathy
24.1.4. Cataract Surgery
24.1.5. Presbyopia
24.2. Patient Access Programs
25. Market Drivers
26. Market Barriers
27. SWOT Analysis
28. Unmet Needs
29. Appendix
29.1. Bibliography
29.2. Report Methodology
30. DelveInsight Capabilities
31. Disclaimer
32. About DelveInsight
List of Tables
Table 1: Summary of Age-related Vision Dysfunction (ARVD), Market, Epidemiology, and Key Events (2018–2030)
Table 2: Vision and aging
Table 3: Risk Factors
Table 4: Recommended Eye Examination Frequency for Adult Patients
Table 5: The American Family Physician Recommendations
Table 6: Screening Recommendations
Table 7: Key clinical recommendations by the American Family Physician Guidelines
Table 8: Prescribing Considerations for Presbyopia
Table 9: Age-Related Macular Degeneration (Management Recommendations)
Table 10: Total Prevalent Cases of Age-related vision dysfunction in the 7MM, in Thousands (2018–2030)
Table 11: Total Diagnosed Cases of Age-related vision dysfunction in the 7MM, in Thousands (2018–2030)
Table 12: Severity-specific Cases of Age-related vision dysfunction in the 7MM, in Thousands (2018–2030)
Table 13: Total Treated Cases of Age-related vision dysfunction in the 7MM, in Thousands (2018–2030)
Table 14: Total Prevalent Cases of Age-related vision dysfunction in the United States, in Thousands (2018–2030)
Table 15: Total Diagnosed Cases of Age-related vision dysfunction in the United States, in Thousands (2018–2030)
Table 16: Severity-specific Cases of Age-related vision dysfunction in the United States, in Thousands (2018–2030)
Table 17: Total Treated Cases of Age-related vision dysfunction in the United States, in Thousands (2018–2030)
Table 18: Total Prevalent Cases of Age-related vision dysfunction in Germany, in Thousands (2018–2030)
Table 19: Total Diagnosed Cases of Age-related vision dysfunction in Germany, in Thousands (2018–2030)
Table 20: Severity-specific Cases of Age-related vision dysfunction in Germany, in Thousands (2018–2030)
Table 21: Total Treated Cases of Age-related vision dysfunction in Germany, in Thousands (2018–2030)
Table 22: Total Prevalent Cases of Age-related vision dysfunction in France, in Thousands (2018–2030)
Table 23: Total Diagnosed Cases of Age-related vision dysfunction in France, in Thousands (2018–2030)
Table 24: Severity-specific Cases of Age-related vision dysfunction in France, in Thousands (2018–2030)
Table 25: Total Treated Cases of Age-related vision dysfunction in France, in Thousands (2018–2030)
Table 26: Total Prevalent Cases of Age-related vision dysfunction in Italy, in Thousands (2018–2030)
Table 27: Total Diagnosed Cases of Age-related vision dysfunction in Italy, in Thousands (2018–2030)
Table 28: Severity-specific Cases of Age-related vision dysfunction in Italy, in Thousands (2018–2030)
Table 29: Total Treated Cases of Age-related vision dysfunction in Italy, in Thousands (2018–2030)
Table 30: Total Prevalent Cases of Age-related vision dysfunction in Spain, in Thousands (2018–2030)
Table 31: Total Diagnosed Cases of Age-related vision dysfunction in Spain, in Thousands (2018–2030)
Table 32: Severity-specific Cases of Age-related vision dysfunction in Spain, in Thousands (2018–2030)
Table 33: Total Treated Cases of Age-related vision dysfunction in Spain, in Thousands (2018–2030)
Table 34: Total Prevalent Cases of Age-related vision dysfunction in the United Kingdom, in Thousands (2018–2030)
Table 35: Total Diagnosed Cases of Age-related vision dysfunction in the United Kingdom, in Thousands (2018–2030)
Table 36: Severity-specific Cases of Age-related vision dysfunction in the United Kingdom, in Thousands (2018–2030)
Table 37: Total Treated Cases of Age-related vision dysfunction in the United Kingdom, in Thousands (2018–2030)
Table 38: Total Prevalent Cases of Age-related vision dysfunction in Japan, in Thousands (2018–2030)
Table 39: Total Diagnosed Cases of Age-related vision dysfunction in Japan, in Thousands (2018–2030)
Table 40: Severity-specific Cases of Age-related vision dysfunction in Japan, in Thousands (2018–2030)
Table 41: Total Treated Cases of Age-related vision dysfunction in Japan, in Thousands (2018–2030)
Table 42: DE-117 Ophthalmic Solution, Clinical Trial Description, 2021
Table 43: Rhopressa (Netarsudil mesylate), Clinical Trial Description, 2021
Table 44: Glanatec, Clinical Trial Description, 2021
Table 45: Ranibizumab, Clinical Trial Description, 2021
Table 46: Aflibercept, Clinical Trial Description, 2021
Table 47: Brolucizumab, Clinical Trial Description, 2021
Table 48: AGN-190584, Clinical Trial Description, 2021
Table 49: MicroLine (Pilocarpine Ophthalmic) Clinical Trial Description, 2021
Table 50: PresbiDrops (CSF-1) Clinical Trial Description, 2021
Table 51: Zimura (avacincaptad pegol), Clinical Trial Description, 2021
Table 52: ALK001, Clinical Trial Description, 2021
Table 53: ONS-5010, Clinical Trial Description, 2021
Table 54: Patent Information
Table 55: KSI-301, Clinical Trial Description, 2021
Table 56: Faricimab, Clinical Trial Description, 2021
Table 57: Abicipar, Clinical Trial Description, 2021
Table 58: RGX-314, Clinical Trial Description, 2021
Table 59: Beovu (Brolucizumab), Clinical Trial Description, 2021
Table 60: STN1013001/DE-130A, Clinical Trial Description, 2021
Table 61: NCX 470, Clinical Trial Description, 2021
Table 62: OTX-TP, Clinical Trial Description, 2021
Table 63: Brimonidine Tartrate Ophthalmic Suspension, Clinical Trial Description, 2021
Table 64: OPT-302, Clinical Trial Description, 2021
Table 65: Conbercept, Clinical Trial Description, 2021
Table 66: AKST4290 (Lazucirnon), Clinical Trial Description, 2021
Table 67: GT005, Clinical Trial Description, 2021
Table 68: ADVM-022, Clinical Trial Description, 2021
Table 69: Emixustat Hydrochloride, Clinical Trial Description, 2021
Table 70: KVD001, Clinical Trial Description, 2021
Table 71: Risuteganib, Clinical Trial Description, 2021
Table 72: GB-102, Clinical Trial Description, 2021
Table 73: AKB-9778, Clinical Trial Description, 2021
Table 74:Nyxol (Phentolamine Mesylate): Clinical Trial Description, 2021
Table 75: STN1012600 (DE-126)/ ONO-9054, Clinical Trial Description, 2021
Table 76: 7MM Market Size of Age-related Vision Dysfunction in USD Million (2018–2030)
Table 77: 7MM Market Size of Age-related Vision Dysfunction by Therapies in USD Million (2018–2030)
Table 78: The United States Market Size of Age-related Vision Dysfunction in USD Million (2018–2030)
Table 79: The United States Market Size of Top 10 Therapies on the Basis of 2030 Revenue in Age-related Vision Dysfunction in USD Million (2018–2030)
Table 80: Germany Market Size of Age-related Vision Dysfunction in USD Million (2018–2030)
Table 81: Germany Market Size of Top 10 Therapies on the Basis of 2030 Revenue in Age-related Vision Dysfunction in USD Million (2018–2030)
Table 82: France Market Size of Age-related Vision Dysfunction in USD Million (2018–2030)
Table 83: France Market Size of Age-related Vision Dysfunction by Therapies in USD Million (2018–2030)
Table 84: Italy Market Size of Age-related Vision Dysfunction in USD Million (2018–2030)
Table 85: Italy Market Size of Age-related Vision Dysfunction by Therapies in USD Million (2018–2030)
Table 86: Spain Market Size of Age-related Vision Dysfunction in USD Million (2018–2030)
Table 87: Spain Market Size of Age-related Vision Dysfunction by Therapies in USD Million (2018–2030)
Table 88: The United Kingdom Market Size of Age-related Vision Dysfunction in USD Million (2018–2030)
Table 89: The United Kingdom Market Size of Age-related Vision Dysfunction by Therapies in USD Million (2018–2030)
Table 90: Japan Market Size of Age-related Vision Dysfunction in USD Million (2018–2030)
Table 91: Japan Market Size of Age-related Vision Dysfunction by Therapies in USD Million (2018–2030)
Table 92: Key HTA Decisions for AMD
Table 93: Key HTA Decisions for Glaucoma
Table 94: Key HTA Decisions for Diabetic Retinopathy
List of Figures
Figure 1: Epidemiology and Market Methodology
Figure 2: Vision with AMD
Figure 3: Vision with DR
Figure 4: Vision with Cataract
Figure 5: Vision with Glaucoma
Figure 6: Vision with Presbyopia
Figure 7: Risk factors of Age-related Vision Dysfunction
Figure 8: Comprehensive Adult Eye and Vision Examination
Figure 9: A Fluorescein angiogram
Figure 10: Amsler grid, as seen by an individual with macular degeneration
Figure 11: Visual Field Test
Figure 12: Slit-lamp Examination
Figure 13: AMD Guidelines
Figure 14: Total Prevalent Cases of Age-related vision dysfunction in the 7MM (2018–2030)
Figure 15: Total Diagnosed Cases of Age-related vision dysfunction in the 7MM (2018–2030)
Figure 16: Severity-specific Cases of Age-related vision dysfunction in the 7MM (2018–2030)
Figure 17: Total Treated Cases of Age-related vision dysfunction in the 7MM (2018–2030)
Figure 18: Total Prevalent Cases of Age-related vision dysfunction in the United States (2018–2030)
Figure 19: Total Diagnosed Cases of Age-related vision dysfunction in the United States (2018–2030)
Figure 20: Severity-specific Cases of Age-related vision dysfunction in the United States (2018–2030)
Figure 21: Total Treated Cases of Age-related vision dysfunction in the United States (2018–2030)
Figure 22: Total Prevalent Cases of Age-related vision dysfunction in Germany (2018–2030)
Figure 23: Total Diagnosed Cases of Age-related vision dysfunction in Germany (2018–2030)
Figure 24: Severity-specific Cases of Age-related vision dysfunction in Germany (2018–2030)
Figure 25: Total Treated Cases of Age-related vision dysfunction in Germany (2018–2030)
Figure 26: Total Prevalent Cases of Age-related vision dysfunction in France (2018–2030)
Figure 27: Total Diagnosed Cases of Age-related vision dysfunction in France (2018–2030)
Figure 28: Severity-specific Cases of Age-related vision dysfunction in France (2018–2030)
Figure 29: Total Treated Cases of Age-related vision dysfunction in France (2018–2030)
Figure 30: Total Prevalent Cases of Age-related vision dysfunction in Italy (2018–2030)
Figure 31: Total Diagnosed Cases of Age-related vision dysfunction in Italy (2018–2030)
Figure 32: Severity-specific Cases of Age-related vision dysfunction in Italy (2018–2030)
Figure 33: Total Treated Cases of Age-related vision dysfunction in Italy (2018–2030)
Figure 34: Total Prevalent Cases of Age-related vision dysfunction in Spain (2018–2030)
Figure 35: Total Diagnosed Cases of Age-related vision dysfunction in Spain (2018–2030)
Figure 36: Severity-specific Cases of Age-related vision dysfunction in Spain (2018–2030)
Figure 37: Total Treated Cases of Age-related vision dysfunction in Spain (2018–2030)
Figure 38: Total Prevalent Cases of Age-related vision dysfunction in the United Kingdom (2018–2030)
Figure 39: Total Diagnosed Cases of Age-related vision dysfunction in the United Kingdom (2018–2030)
Figure 40: Severity-specific Cases of Age-related vision dysfunction in the United Kingdom (2018–2030)
Figure 41: Total Treated Cases of Age-related vision dysfunction in the United Kingdom (2018–2030)
Figure 42: Total Prevalent Cases of Age-related vision dysfunction in Japan (2018–2030)
Figure 43: Total Diagnosed Cases of Age-related vision dysfunction in Japan (2018–2030)
Figure 44: Severity-specific Cases of Age-related vision dysfunction in Japan (2018–2030)
Figure 45: Total Treated Cases of Age-related vision dysfunction in Japan (2018–2030)
Figure 46: How The Pinhole Effect Focuses Light
Figure 47: Mechanism of Action of OPT-302
Figure 48: Mechanism of action of Risuteganib
Figure 49: Mechanism of action of GB-102
Figure 50: Mechanism of action of AKB-9778
Figure 51: Market Size of Age-related Vision Dysfunction in the 7MM, USD Million (2018–2030)
Figure 52: 7MM Market Size of Top 10 Therapies on the Basis of 2030 Revenue in Age-related Vision Dysfunction in USD Million (2018–2030)
Figure 53: Market Size of Age-related Vision Dysfunction in the United States, USD Million (2018–2030)
Figure 54: The United States Market Size of Top 10 Therapies on the Basis of 2030 Revenue in Age-related Vision Dysfunction in USD Million (2018–2030)
Figure 55: Market Size of Age-related Vision Dysfunction in Germany, USD Million (2018–2030)
Figure 56: Germany Market Size of Top 10 Therapies on the Basis of 2030 Revenue in Age-related Vision Dysfunction in USD Million (2018–2030)
Figure 57: Market Size of Age-related Vision Dysfunction in France, USD Million (2018–2030)
Figure 58: France Market Size of Top 10 Therapies on the Basis of 2030 Revenue in Age-related Vision Dysfunction in USD Million (2018–2030)
Figure 59: Market Size of Age-related Vision Dysfunction in Italy, USD Million (2018–2030)
Figure 60: Italy Market Size of Top 10 Therapies on the Basis of 2030 Revenue in Age-related Vision Dysfunction in USD Million (2018–2030)
Figure 61: Market Size of Age-related Vision Dysfunction in Spain, USD Million (2018–2030)
Figure 62: Spain Market Size of Top 10 Therapies on the Basis of 2030 Revenue in Age-related Vision Dysfunction in USD Million (2018–2030)
Figure 63: Market Size of Age-related Vision Dysfunction in the United Kingdom, USD Million (2018–2030)
Figure 64: The United Kingdom Market Size of Top 10 Therapies on the Basis of 2030 Revenue in Age-related Vision Dysfunction in USD Million (2018–2030)
Figure 65: Market Size of Age-related Vision Dysfunction in Japan, USD Million (2018–2030)
Figure 66: Japan Market Size of Top 10 Therapies on the Basis of 2030 Revenue in Age-related Vision Dysfunction in USD Million (2018–2030)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings